Bristol Myers Squibb's RYZ101 meets primary endpoint in phase 3 GEP-NET trial
Tweet Send to a Friend
Bristol Myers Squibb (NYSE: BMY) announced that its investigational radiopharmaceutical RYZ101 met the primary endpoint in the planned interim analysis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




